Ligand Pharmaceuticals Inc (NAS:LGND)
$ 81.36 -1.01 (-1.23%) Market Cap: 1.46 Bil Enterprise Value: 1.16 Bil PE Ratio: 15.29 PB Ratio: 1.81 GF Score: 76/100

Q4 2021 Ligand Pharmaceuticals Inc Earnings Call Transcript

Feb 17, 2022 / 09:30PM GMT
Release Date Price: $69.97 (-8.43%)
Operator

Good day and thank you for standing by and welcome to the Ligand Pharmaceuticals Q4 Earnings Call. (Operator Instructions) Please be advised that this call is being recorded (Operator Instructions)

I would now like to hand the conference over to your host today, Simon Latimer, Head of Investor Relations. You may begin.

Simon Latimer

Thank you, Justin. Welcome to Ligand's Fourth Quarter of 2021 Financial Results and Business Update Conference Call. Our speakers for today's call are in separate locations. Speaking today for Ligand will be John Higgins, CEO; Matt Foehr, COO; and Matt Korenberg, CFO.

We will use non-GAAP financial measures and some of our statements will be forward-looking, including those related to our financial condition, results of operations, financial guidance and the impact of the COVID-19 pandemic and plans for OmniAb to become a standalone public company. Additional information concerning risk factors and other matters concerning Ligand can be found in our earnings press release and our periodic filings with the SEC. We

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot